Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2026-05-19 am EDT			5-day change	1st Jan Change
287.50 ^DKK	+0.52%		-3.04%	-11.61%

09:14am	Can Nvidia Do It Again?
08:12am	Novo Nordisk highlights semaglutide for the treatment of silent liver disease	FW

NOVO NORDISK : Jefferies reaffirms its Neutral rating

Published on 04/20/2026 at 07:39 am EDT

MarketScreener with dpa-AFX Analyser

NOVO NORDISK A/S

+0.52%

Michael Leuchten from Jefferies retains his Neutral opinion on the stock. The target price remains set at DKK 270.

Latest news about Novo Nordisk A/S

09:14am	Can Nvidia Do It Again?
08:12am	Novo Nordisk highlights semaglutide for the treatment of silent liver disease	FW
08:11am	Novo Nordisk to present semaglutide data on liver disease	RE
07:13am	NOVO NORDISK : Barclays reiterates its Neutral rating	ZD
04:29am	Big Pharma Firms Denied Certiorari by Supreme Court in Medicare Pricing Case	MT
02:13am	The stock market still recoils at the prospect of higher rates
12:37am	Novo Nordisk Says 'Disappointed' by US Supreme Court Decision in Medicare Drug Pricing Case	MT
May. 18	Top Midday Stories: NextEra, Dominion to Combine in All-Stock Deal; Big Pharma Firms Denied Certiorari by Supreme Court in Medicare Pricing Case	MT
May. 18	Big Pharma Firms Denied Certiorari by Supreme Court in Medicare Pricing Case	MT
May. 18	Big Pharma Firms Denied Certiorari by Supreme Court in Medicare Pricing Case	MT
May. 18	US Supreme Court rebuffs pharma challenge to Biden-era drug price	RE
May. 18	Novo Nordisk slides on signs of slowing sales momentum for Wegovy pill	FW
May. 15	European Equities Traded in the US as American Depositary Receipts Down Sharply in Friday Trading	MT
May. 15	Sandoz Lands EU Nod for Insulin Biosimilars Bysumlog, Dazparda	MT
May. 15	Baillie Gifford European repositions portfolio as asset value falls	AN

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (93.7%); - rare disease treatment products (6.3%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe and Canada (21.4%), the United States (56%), Latin America/Middle East/Africa (9.9%), China/Hong Kong/Taiwan (6%), Asia/Pacific (6.7%).

Employees

67,900

Sector

Pharmaceuticals

Calendar

Earnings release - Q2 2026

More about the company